In short
Pacira Biosciences, Inc. (PCRX) has revenue up 3.6% to $726.4M and net income up 107.1% to $7.0M year on year. Its net margin is 1.0%, and it trades at 39.2× trailing earnings. Fisclear found no medium- or high-severity risk flags in this filing. How we calculate this
Valuation
HealthcareLive · Yahoo FinancePrice
$36.48
$1.5B
12.7x
52-Week Range
Decision Context
Market appears to be pricing in less growth than this company's historical average, suggesting potential upside if the trajectory continues. Quality and efficiency scores support the business case.
Based on filing period ending Sept 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.88%
Accommodative
10-Year Treasury
5.13%
2026-10-01
Unemployment
4.1%
Near full employment
CPI Index
336.3
2026-09-01
M2 Money Supply
$23.4T
2026-09-01
The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.1%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.
SWOT Analysis — PCRX
Inflationary BoomStrengths
EPS (Diluted): $0.16 (+107.4% YoY) — Earnings per share rose 107% — each share earned more.
Net Income: $7.0M (+107.1% YoY) — Profit grew 107% — the company kept more of each dollar earned.
Weaknesses
Operating Cash Flow: $152.0M (-19.7% YoY) — Operating cash flow fell 20% but remained positive.
Total Assets: $1.3B (-18.6% YoY) — Total assets shrank 19% — the balance sheet contracted.
Stock is near its 52-week high (36.67) — the price reflects strong recent momentum, but entry risk is elevated at these levels.
Opportunities
Revenue: $726.4M (+3.6% YoY) — Revenue grew 4% — the company sold more goods or services than the prior year.
Threats
No significant threats flagged.
Year-over-Year Changes
EPS (Diluted)
$0.16
was $-2.15
Earnings per share rose 107% — each share earned more.
Net Income
$7.0M
was -$99.6M
Profit grew 107% — the company kept more of each dollar earned.
Operating Cash Flow
$152.0M
was $189.4M
Operating cash flow fell 20% but remained positive.
Total Assets
$1.3B
was $1.6B
Total assets shrank 19% — the balance sheet contracted.
Revenue
$726.4M
was $701.0M
Revenue grew 4% — the company sold more goods or services than the prior year.
Risk Flags
0 high · 0 medium · 1 low- ○ Low
Stock is near its 52-week high (36.67) — the price reflects strong recent momentum, but entry risk is elevated at these levels.
Technical Signals
Daily closes · 1-year dataPacira Biosciences, Inc.: common questions
Is Pacira Biosciences, Inc. profitable?
Yes. Pacira Biosciences, Inc. made a net profit of $7M in its latest fiscal year (fiscal 2025), a net margin of 1.0%.
Is Pacira Biosciences, Inc.'s revenue growing?
Yes. Revenue grew 3.6% year on year, to $726.4M.
What is Pacira Biosciences, Inc.'s P/E ratio?
Pacira Biosciences, Inc. trades at 39.2× its trailing twelve-month earnings. In other words, the share price is about 39 times the profit per share the company earned over the past year.
Does Pacira Biosciences, Inc. pay a dividend?
No dividend is currently expected from Pacira Biosciences, Inc., according to the latest market data.
Answers are generated from the figures in this report (updated 7 Nov 2026). Information, not investment advice.
Latest News
via FinnhubFiling History — PCRX
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade PCRX
Links open broker research pages. Not an endorsement or recommendation.
Research Pacira Biosciences, Inc.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.